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biochemical and immunohistochemical markers related to atherosclerosis 
and atherosclerosis development in the aorta of apolipoprotein E knockout 
[Apo-E (−/−)] mice were evaluated in this study. Empagliflozin-treated 
mice had lower total cholesterol (P<0.05), fasting glucose (P<0.01), 
heart rate (P<0.01) and diastolic blood pressure (DBP) (P<0.05) compared 
to controls. Histomorphometry revealed reduced atherosclerotic lesion 
progress approaching statistical significance (P=0.06) and approximately 
50% wider lumen area for the Empagliflozin treated mice group. Although 
empagliflozin significantly reduced VCAM-1 and MCP-1 (P<0.05, P<0.01, 
respectively) and marginally induced TIMP-1 and TIMP-2 mRNA expression 
(P< 0.08, P=0.1 respectively), immunohistochemistry revealed a marginal 
reduction in VCAM-1 and MMP-9 (P= 0.1) without affecting the expression 
of TIMP-2 and MCP-1 in atherosclerotic lesions. 
Empagliflozin improves primary haemodynamic parameters and attenuates the 
progression of atherosclerosis by reducing hyperlipidemia and 
hyperglycemia, while direct actions in aorta vessel mediated via SGLT-1 
are strongly hypothesized
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49 Abstract 
50 
51 The effects of long-term treatment with empagliflozin on biochemical and 
52 immunohistochemical markers related to atherosclerosis and atherosclerosis 
53 development in the aorta of apolipoprotein E knockout [Apo-E (−/−)] mice were 
54 evaluated in this study. Empagliflozin-treated mice had lower total cholesterol 
55 (P<0.05), fasting glucose (P<0.01), heart rate (P<0.01) and diastolic blood pressure 
56 (DBP) (P<0.05) compared to controls. Histomorphometry revealed reduced 
57 atherosclerotic lesion progress approaching statistical significance (P=0.06) and 
58 approximately 50% wider lumen area for the Empagliflozin treated mice group. 
59 Although empagliflozin significantly reduced VCAM-1 and MCP-1 (P<0.05, P<0.01, 
60 respectively) and marginally induced TIMP-1 and TIMP-2 mRNA expression (P< 0.08, 
61 P=0.1 respectively), immunohistochemistry revealed a marginal reduction in VCAM-1 
62 and MMP-9 (P= 0.1) without affecting the expression of TIMP-2 and MCP-1 in 
63 atherosclerotic lesions. 
64 Empagliflozin improves primary haemodynamic parameters and attenuates the 
65 progression of atherosclerosis by reducing hyperlipidemia and hyperglycemia, while 
66 direct actions in aorta vessel mediated via SGLT-1 are strongly hypothesized. 
67 
68 
69 Keywords: Empagliflozin, SGLT2i, Atherosclerosis, Inflammation, APOE knockout mice 
70 
71 
72 Abbreviations 
73 SGLT2: sodium glucose co-transporter2; SGLT2i: sodium glucose co-transporter2 
74 inhibitor; T2DM: type 2 diabetes mellitus; APOE(−/−): apolipoprotein E knockout Apo- 
75 E(−/−); CV: cardiovascular; CVD: cardiovascular disease; MCP-1: monocyte 
76 chemoattractant protein 1; CD68: cluster of differentiation 68; MMP-2: matrix 
3  
77 metalloproteinase- 2; MMP-9: matrix metalloproteinase-9; TIMP-1: tissue inhibitor of 
78 metalloproteinases-1; TIMP-2: tissue inhibitor of metalloproteinases-2; ICAM-1: 
79 intercellular adhesion molecule 1; VCAM-1: vascular cell adhesion molecule 1; Empa: 
80 empagliflozin; ECM: extracellular matrix; HbA1c: hemoglobin A1c; Il-6: interleukin 6; 
81 HFD: high fat diet; DBP: diastolic blood pressure; SBP: systolic blood pressure. 
82 
83 1. Introduction 
84 
85 Type  2  diabetes  (T2DM)  prevalence  rates  have  been  increasing  during  the  past 
86 decades, in parallel to the documented obesity epidemic [NCD-RisC, 2016; Zimmet et 
87 al. 2016]. T2DM comprises up to 90% of all diabetic cases in adults, with the most 
88 recent International Diabetes Federation (IDF) estimates indicating that 415 million 
89 adults (1 in 11 adults) have diabetes, a number predicted to reach 642 million (1 in 10 
90 adults)  by  2040  [IDF,  2015].  Furthermore,  close  pathogenic  links  exist   between 
91 diabetes and cardiovascular disease (CVD), with CVD currently representing the main 
92 cause of morbidity/mortality in diabetic patients (up to 80% of all diabetic patients 
93 die from CVD-related events) [ESC 2013; Matheus et al. 2013]. It becomes evident 
94 that T2DM-related cardio-metabolic disease poses a significant challenge in clinical 
95 practice, requiring new effective treatment options which will lower the disease 
96 burden and particularly the associated CVD risk. 
97 
98 Despite advances in our understanding of T2DM pathophysiology, so far the applied 
99 glucose-lowering strategies have had little or no impact on CVD progression/outcomes 
100 in T2DM patients, whilst only a limited number of new medications have been added 
101 to the arsenal against the current diabesity epidemic [e.g. incretin mimetics and 
102 sodium/glucose cotransporter 2 (SGLT2) inhibitors] [Bolen S, et al. 2016; Thompson et 
103 al. 2016]. Moreover, the complete spectrum of effects of these new anti-diabetic 
104 agents has not been fully clarified yet. In this context, current research is focused  on 
105 exploring the exact effects/outcomes of the new anti-diabetic medications [e.g. of 
106 glucagon-like peptide-1 (GLP-1) agonists and SGLT2 inhibitors] not only in controlling 
107 hyperglycaemia, but also on T2DM-related CVD. Indeed, following the lack of success 
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108 in significantly controlling CVD progression in T2DM with previous anti-diabetic 
109 medications and tight glycaemic control, there is now increasing evidence indicating 
110 that certain newer anti-diabetic agents, particularly GLP-1 agonists (e.g. liraglutide) 
111 and SGLT2 inhibitors (e.g. empagliflozin and dapagliflozin) will offer significant CVD 
112 benefits independent of glycaemic control [Thompson et al. 2016; Flory et al. 2016]. 
113 113 
114 SGLT2 inhibitors constitute the newest class of anti-diabetic medications which act by 
115 increasing urinary glucose excretion, and, hence, improve glycaemic control 
116 independently of insulin secretion [Heerspink et al. 2016; Marx et al. 2016]. Recently, 
117 the EMPA-REG OUTCOME trial, a key CVD outcome trial, showed that empagliflozin 
118 significantly lowered the combined CVD endpoint of CVD death, non-fatal stroke and 
119 non-fatal myocardial infarction in T2DM patients with prevalent CVD [Zinman et al. 
120 2015]. Moreover, empagliflozin unexpectedly induced a significant reduction in the 
121 individual endpoints of CVD death, heart failure hospitalization and overall mortality 
122 in this high CVD risk population of T2DM patients. Of note, a recent meta-analysis by 
123 Zelniker et al. showed that the benefits of SGLT-2 inhibitors are more pronounced in 
124 patients with established atherosclerotic CVD [Zelniker et al. 2019]. Thus, much 
125 research focus has been placed on elucidating the mechanisms responsible for these 
126 beneficial CVD effects of SGLT2 inhibition, which appear to extend beyond glucose 
127 control,  potentially  including  mechanisms  relating  to  weight  loss,  blood pressure 
128 lowering and sodium depletion, neuro-hormonal and renal haemodynamic effects, and 
129 effects on myocardial energetics/signalling [Heerspink et al. 2016; Marx et al. 2016]. 
130 130 
 
131 In the present study, we aimed to investigate the long-term effect of empagliflozin 
132 using a dose of 10 mg/Kg/day on atherosclerosis development in the aorta of the 
133 APOE (-/-) atherosclerosis mouse model focusing particularly on its role in local factors 
134 related to atheroma plaque stability. Furthermore, classic CVD risk factors such as 
135 hyperlipidemia, hypertension, weight gain and inflammation were evaluated. 
 
136 2. Materials and Methods 
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137 2.1 Animals 
 
138 APOE (-/-) mice (C57BL/6J-ApoEtm1Unc) were originally purchased from “The Jackson 
139 Laboratory” and bred in the animal facility of National and Kapodistrian University of 
140 Athens. Mice were kept at specific pathogen free (SPF) controlled environment (22– 
141 26 °C temperature, 40–60% humidity and 12h light/dark cycle). Animal experiments 
142 were approved by the local Animal Care and Use Committee. 
 
143 2.2 Experimental protocols 
 
144 20 male APOE (-/-) mice were kept on a standard rodent chow. At the age of 5 weeks, 
145 mice were switched to high fat diet (HFD- mucedola-Italy) (20–23% by weight; 40–45% 
146 kcal from fat) containing cholesterol (0.2% total). After 5 weeks on HFD, mice were 
147 randomly divided into two groups (1) Empagliflozin-group 10 mg/kg/day (n=10) 
148 administered orally by gavage, and (2) control-group (n=10) administered the same 
149 volume of 0.5% hydroxypropyl methylcellulose /day (vehicle), via gavage. After 
150 10 weeks of treatment with Empagliflozin or vehicle, mice were culled under 
151 isoflurane anesthesia by transection of the diaphragm and, the aorta along with heart 
152 were rapidly excised. Food intake and body weight were measured once weekly over a 
153 period of 10 weeks. Blood glucose levels were measured after 8–10h fast via tail 
154 puncture at baseline, before Empagliflozin/vehicle oral administration, once during 
155 experiment (5 week) and before the end of the experiment. Empagliflozin was 
156 purchased from MCE (Cat. No. HY-15409) and dissolved in 0.5% hydroxypropyl 
157 methylcellulose (Sigma). 
 
158 2.2.1 Blood pressure measurement 
 
159 Blood pressure was measured using a computerized non-invasive tail-cuff system 
160 (CODAs, Kent Scientific, USA) [Nasiri-Ansari et al. 2018] once at baseline, before 
161 Empagliflozin administration began and once before culling animals as described 
162 previously. All measurements are reported as mean values of heart rate, systolic and 
163 diastolic blood pressure. 
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164 2.2.2 Serum analysis of biochemical parameters 
 
165 Venipuncture was performed once before the onset of Empagliflozin administration 
166 from the facial vein and once by heart puncturing after culling the mice. Serum 
167 glucose, total-cholesterol, triglycerides, and HDL- and LDL-cholesterol levels were 
168 determined using a dedicated autoanalyzer. 
 
169 2.2.3 RNA isolation and real time PCR 
 
170 Total RNA was extracted from fresh frozen aorta using NucleoSpin RNA Plus kit 
171 (MACHEREY-NAGEL). Extracted mRNA was then reverse transcribed into cDNA using 
172 the iScript cDNA synthesis kit (Bio-Rad). Real-time PCR analysis was performed as 
173 described previously [Nasiri-Ansari et al. 2018]. The expression of Matrix 
174 Metalloproteinase -2 and -9 (MMP-2 and MMP-9) and their inhibitors (TIMP-1 and TIMP- 
175 2), IL-6, intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 
176 (VCAM-1) and monocyte chemotaxis protein 1 (MCP-1) was measured using 
177 Luna® Universal qPCR Master Mix (New England Biolabs) on a CFX96 (Bio-RAD). The 
178 sequences of primers used for RT-PCR analysis in this study are listed in Table 1. A 
179 melting curve analysis was performed to confirm the specificity of qPCR products. 
180 Fold-changes were calculated using the 2−∆∆Ctmethod and were normalized against 18s 
181 mRNA expression. All reactions were performed in triplicates and repeated at least 
182 three times. 
 
183 3. Histochemistry and immunohistochemistry 
 
184 3.1 Quantification of atherosclerotic lesion area 
 
185 Aortic tissues were fixed and embedded in paraffin. The 4-μm-thick sections were 
186 stained with hematoxylin–eosin (H&E) and used for histopathological analysis whereas 
187 Masson’s trichrome stained sections were used to quantify tissue section’s collagen 
188 content. The degree of pathological changes was evaluated microscopically by 
189 measuring the area of atheromatous plaque. Results are reported as the percentage 
190 of the neointima area containing the lesion. Threshold was set and the positively 
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191 stained area for each histochemical stain was automatically calculated and then the 
192 percent of the positively stained area to the total cross-sectional vessel wall area or 
193 intimal plaque lesion area was reported. Plaque area analysis was carried out using 
194 Image Pro Plus software version 5.1 (Media Cybernetics, Inc.). 
 
195 3.1.1 Immunohistochemistry 
 
196 All sections were deparaffinized at 60 °C. Antigen retrieval was performed using 
197 citrate buffer (PH.6.0) for 7 min at 100 °C followed by blocking with normal goat 
198 serum (CST, 5425S) for 1 h. Slides were then incubated with appropriate 
199 concentration of primary antibodies against CD68 (ZYTOMED, MSK055), α-smooth 
200 muscle actin (ZYTOMED, MSK030), MCP-1 (ACRIS, AM32136PU-N), MMP-2 (Proteintech 
201 Group, 103732-AP), MMP-9 (Proteintech Group, 10375-2-AP) and their inhibitors TIMP- 
202 1 (Santa Cruz Biotechnology, sc-21734) and TIMP-2 (Santa Cruz Biotechnology, sc- 
203 21735), ICAM-1 (Santa Cruz Biotechnology, , sc-8439) , VCAM-1 (Santa Cruz 
204 Biotechnology, sc-13160) followed by incubation with corresponding secondary 
205 antibody conjugated to horseradish peroxidase (ZYTOMED, ZUC053-100) and visualized 
206 by applying DAB (CST.8059P). All slides were counterstained with hematoxylin and 
207 integral absorbance was examined under light microscope and results were quantified 
208 using Image Pro Plus software version 5.1 (Media Cybernetics, Inc.). A positive tissue 
209 control was used to ensure the specificity of antibodies used in this study. 
 
210 210 
 
211 3.1.2 Statistical analysis 
 
212 We used Student's t-test, Welch's test or Mann-Whitney test, after assessing the 
213 normality of data distribution with the Shapiro-Wilk test and the equality of variances 
214 with the Levene's test, for comparisons between EMPA and control animals regarding 
215 quantitative variables, namely weight, heart rate, blood pressure, biochemical blood 
216 test results, PCR results, and plaque area, lumen area and collagen content in 
217 immunohistochemical analysis. We used the Chi-square test or the Fisher's exact test, 
218 as appropriate, for comparisons between EMPA and control animals concerning 
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219 qualitative variables from immunohistochemical analysis, namely MMP-2, MMP-9, 
220 TIMP-1, α-ACTIN, CD-68, MCP-1, VCAM-1 and ICAM-1. We included a paired t-test for 
221 comparing the same parameter in each animal before and after intervention. 
222 All tests were two-tailed and results were considered statistically significant if P- 
223 value was less than 0.05. Statistical analysis was performed using the 23nd edition of 
224 Statistical Package for Social Sciences (SPSS) (IBM Corporation, Armonk, NY, USA). 
 
225 225 
 
226 4. Results 
 
227 4.1 Oral administration of Empagliflozin for 10 weeks improved diastolic blood 
228 pressure, heart rate and reduced fasting blood glucose levels 
 
229 No significant difference in daily food intake was observed between the two groups. 
 
230 Body weight was significantly increased in both groups after feeding HFD and 
231 10 weeks of oral Empagliflozin/vehicle  administration compared  to the value 
232 measured at experiment baseline. No significant difference in weight gain was 
233 observed between Empagliflozin and control group (data not shown but available in 
234 supplementary material-supplementary Figure 1). 
 
235 Fasting blood glucose (8 h of fasting) and serum lipid levels were measured before 
236 Empagliflozin/vehicle oral administration as well as at the end of intervention period. 
237 A significant reduction in glucose and total cholesterol levels (P<0.01 and P<0.05 
238 respectively) along with a significant induction in HDL levels (P<0.05) were observed 
239 in Empagliflozin group at the end of intervention period compared to value measured 
240 at baseline. No significant changes in serum LDL was observed after 10 weeks of 
241 Empagliflozin/vehicle oral treatment (Figures 1.a & 1.b). Importantly, treatment with 
242 Empagliflozin, restored glucose levels to normal, contrary to placebo group where 
243 glucose increased significantly indicating progression to diabetes (P<0.01). 
 
244 At the end of Empagliflozin/vehicle oral treatment, there was a significant difference 
245 from baseline only in fasting glucose (P<0.01) between the two groups. Mean±SD 
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246 changes in triglycerides, total cholesterol, LDL-, HDL-cholesterol and creatinine levels 
247 from baseline were not significantly different between the two groups (Figure 1.b) 
 
248 Empagliflozin administration significantly reduced heart rate (P≤0.01), whereas no 
249 significant change was observed in the control group. In contrast, diastolic blood 
250 pressure values were significantly higher in the control group at experiment endpoint 
251 compared to values measured before the intervention (P<0.05) (Figure 2.a). This 
252 finding was confirmed by comparing diastolic blood pressure and heart rate changes 
253 from baseline (values measured before onset of Empagliflozin/vehicle oral 
254 administration) between the two groups. (P<0.05 and P≤0.01 respectively) (Figure 
255 2.b). Ten weeks of Empagliflozin/vehicle intervention had no significant effect on 
256 systolic blood pressure (Figure 2.a). 
 
257 257 
 
258 4.2 Empagliflozin reduces atherosclerotic lesion area albeit has no effect 
259 on atherosclerotic plaque collagen content 
 
260 Empagliflozin administration for 10 weeks significantly reduced atherosclerotic lesion 
261 progress. Six out of ten mice in the Empa-group and eight out of ten mice in the 
262 control-group developed atherosclerotic plaque. 
 
263 Atherosclerotic plaque presence was assessed using H&E staining (representative 
264 Figure 3.a). Atherosclerotic lesion area was quantified measuring the percentage of 
265 lumen area covered by total plaque area in all aortic root sections, and the mean 
266 plaque area (±SD) was then calculated for each group (Figure 3.b). The lumen area 
267 was wider (by approximately 50%) in Empa-group compared with control-group 
268 (P=0.06). Masson Trichrome staining showed that atherosclerotic lesions in both 
269 groups had similar collagen content (P=0.6). Images and quantitative data are 
270 presented in Figures 3.a &3.b. 
 
271 271 
 
272 4.3 Empagliflozin reduced the expression of inflammatory molecules and 
273 improved metalloproteinase profile 
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274 The effect of Empagliflozin treatment on the expression of inflammatory and 
275 adhesion molecules (IL-6, MCP-1 & ICAM-1, VCAM-1 respectively), matrix 
276 metalloproteinases (MMP-2, MMP-9) and their inhibitors (TIMP-1, TIMP-2), was 
277 investigated, isolating total RNAs from the aortic root and analyzed using real-time 
278 quantitative RT-PCR. 
 
279 We demonstrate that oral Empagliflozin administration significantly reduces VCAM-1 
280 and MCP-1 mRNA levels (P<0.01 and P<0.05 respectively) while it induces TIMP-1 
281 mRNA expression levels trending towards statistical significance (P=0.085) (Figure 
282 4.a). Empagliflozin treatment causes no significant alteration in IL-6, ICAM-1, TIMP-2, 
283 MMP-2 and MMP-9 mRNA levels compared to control group. 
 
284 A balance between MMPs and TIMPs is known as an indicator of MMPs overall 
285 collagenolytic activity. To this end, TIMP-1/MMP-2 ratio mRNA levels were measured. 
286 Our findings demonstrate that TIMP-1/MMP-2 mRNA levels ratio was significantly 
287 higher in Empa-group (P<0.05) compared to control group. (Figure 4.b) 
 
288 Immunohistochemistry staining of aortic root section revealed that Empagliflozin 
289 treatment marginally reduced CD-68 and MMP-9 protein levels while marginally 
290 induced TIMP-1 expression in atherosclerotic lesions compared to the control group 
291 (P=0.1) (Figure 5). 
 
292 Although an increase in the expression of α-ACTIN, TIMP-2, and a borderline decrease 
293 in MCP-1, MMP-2, and ICAM-1 active-protein expression was observed in Empa-group 
294 compared to control group, the differences were not statistically significant (data not 
295 shown but available in supplementary material-supplementary Figure 2). 
 
296 296 
297 5. Discussion 
298 298 
299 Although clinical trials have showed the anti-atherogenic effects of SGLT2-i in 
300 patients with T2DM, providing data for primary and secondary prevention for CVD, the 
301 exact mode of their direct and/or indirect actions mediating this effect is not fully 
302 explored yet [Heerspink et al. 2016; Marx et al. 2016]. Interestingly, according to the 
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303 EMPA-REG OUTCOME Trial, reductions in key CV outcomes and mortality with 
304 empagliflozin vs placebo were consistent across the wide spectrum of CV risk 
305 [Fitchett et al. 2018]. 
 
306 Herein, we investigated the long term effect of empagliflozin using a higher dose of 
307 10mg/Kg/day, contrary to what has been used by others previously [Han et al. 2016] 
308 on atherosclerosis development in the aorta of APOE(-/-) mice with high fat diet- 
309 induced atheromatosis. 
 
310 In contrast to human studies [Lee et al. 2018], empagliflozin did not reduce body 
311 weight in APOE(-/-) compared to control group. Both groups, consuming similar 
312 amounts of food, gained weight without significant differences among them. Previous 
313 studies have showed that empagliflozin for 8 weeks decreased body weight in 
314 APOE(−/−) mice at a dose 1-3mg/Kg/day, while it did not affect significantly the weight 
315 of ZDF rats (type 2 diabetes model) at a dose of 10 and 30mg/Kg/day [Han et al. 
316 2016, Steven et al. 2017]. 
317 Interestingly, a recent study of an orally administered small molecule (LX4211) that 
318 inhibits both intestinal SGLT1 and renal SGLT2, and improves glycaemic control in 
319 both humans and mice, showed divergent effects regarding body weight, increasing it 
320 in mice – through hyperphagia- but not in humans [Powell et al. 2014]. Apart from 
321 species-specific differences and differences in animal models used (obese, non-obese, 
322 diabetic, atherosclerotic etc.) other mechanisms implicating  dose- and time- 
323 dependent effects on energy expenditure and/or activity could also provide possible 
324 explanations for these conflicting results. 
325 In our study, total cholesterol decreased, and HDL-cholesterol increased following 
326 long-term administration of empagliflozin. Regarding HDL-cholesterol, our data are in 
327 line with previous studies demonstrating that empagliflozin given at a lower dose of 
328 3mg/Kg/day – but not 1mg/Kg- for 8 weeks in APOE(-/-) mice, resulted in increased 
329 HDL. No changes were observed in LDL-cholesterol. Interestingly, most clinical studies 
330 using various SGLT-2i reported increased LDL levels, while animal studies resulted in 
331 conflicting results [Kusaka et al. 2013, Leng et al. 2016, Steven et al. 2017, Nakatsu 
332 et al. 2017, Filippas-Ntekouan et al. 2018, Ji et al. 2017]. 
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333 According to a recent work by Basu et al. [2018] SGLT2 inhibition, leads to increased 
334 LDL-cholesterol via reducing clearance of LDL from circulation. 
 
335 Interestingly, triglyceride levels were not changed although the study by Han et al., 
336 showed  that  lower  doses  of  empagliflozin  for  8  weeks  led  to  decreased   serum 
337 triglycerides.  These contrasting  results could be  attributed to  the  higher doses and 
338 the longer duration of treatment. We assume that higher doses of empagliflozin could 
339 result in SGLT1 binding which is known to regulate glucagon secretion [Han et al. 
340 2016]. It has been demonstrated that higher expression of SGLT1 in islets is associated 
341 with higher glucagon secretion [Suga et al. 2019]. Although empagliflozin has the 
342 higher selectivity for SGLT2 among other SGLT2i [Anker et al. 2018], in high serum 
343 concentrations such those achieved by administration of 10mg/Kg/day, could 
344 decrease glucagon secretion via inhibiting SGLT1 in α cells. A decrease in glucagon 
345 levels, a hormone that suppresses de novo synthesis of triglycerides in the liver and 
346 attenuates NAFLD [Wang et al. 2016], could counteract the favorable effects of 
347 empagliflozin on insulin sensitivity [Karen et al. 2016]. Although, we didn’t measure 
348 glucagon levels, we found increased hepatic steatosis and inflammation in the Empa- 
349 group compared to control-group, strengthening this notion (unpublished data). 
 
350 Herein, we demonstrated a beneficial effect on DBP while SBP remained unchanged. 
351 Although clinical trials have demonstrated the beneficial effects of empagliflozin on 
352 blood pressure reducing daytime, 24-hour, morning home and clinic SBP at 12 weeks 
353 [Kario et al. 2018], animal studies have yielded conflicting results [Terami et al. 
354 2014, Terasaki et al. 2015, Ishibashi et al. 2016, Habibi et al. 2017, Hammoudi et al. 
355 2017, Tahara et al. 2018]. Empagliflozin given at the same dose as in our study but 
356 over a shorter duration (5 weeks), improved glycemic control but didn’t decrease 
357 either SBP or DBP [Aroor et al. 2018]. 
358 A possible explanation for our findings is the empagliflozin-induced increase in eNOS 
359 activity [Aroor et al. 2018], an effect that could result in the decrease in DBP. It has 
360 been previously reported that eNOS gene exerted effects on DBP [Zhu et al. 2005]. 
361 Moreover, empagliflozin has been reported to promote cardiac diastolic relaxation via 
362 modulation SGK1/ENaC profibrosis signaling and associated interstitial fibrosis [Habibi 
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363 et al. 2017, Lin et al. 2014]. It is important to note that recent study by Xu et al [Xu 
364 et al. 2019] showed that mice fed high fat diet for a period of 16 weeks increased 
365 their diastolic pressure while systolic pressure remained unchanged. Thus, it seems 
366 that empagliflozin managed to counteract the detrimental effects of high fat diet on 
367 diatolic blood pressure. 
 
368 We demonstrated additionally, a significant decrease in heart rate with empagliflozin. 
369 A recent study in humans showed that a decrease in resting heart rate at the end of 
370 24 weeks of treatment with tofogliflozin was not correlated with changes in body 
371 weight, HbA1c and SBP but with changes in insulin resistance [Matsubayashi et al. 
372 2018]. Thus, although we did not measure insulin levels, it can be hypothesized, that 
373 the decrease in heart rate we demonstrate could be attributed to the suppression of 
374 sympathetic nervous system activity by amelioration of hyperinsulinemia. Indeed, 
375 empagliflozin has been found by others to reduce insulin levels and improve insulin 
376 resistance estimated by HOMA-IR model [Kusaka et al. 2016]. 
377 Although the number of mice with atherosclerotic lesions did not differ significantly 
378 between the two groups, there was a marginal reduction that almost approached 
379 significance in aortic root plaque area (approximately by 50%-P=0.06) in Empa-group 
380 compared to controls. The beneficial effects on lipids profile and DBP could 
381 contribute to the decrease in plaque formation. Attenuation of atherosclerosis 
382 process could also be attributed to the glucose-lowering effects of empagliflozin. 
383 Nevertheless, Han et al., reported that the beneficial sequelae of empagliflozin on 
384 atheromatosis in APOE(-/-) mice were exerted irrespective of achieved glucose 
385 homestasis, since the group treated with glimepiride had similar glycemic control 
386 without improvement in atheroma formation [Han et al. 2016]. The same study 
387 reported a beneficial effect of empagliflozin on atheroma formation in the aortic root 
388 (with 25% reduction) when given at a dose of 1 and 3mg/Kg/day for 8 weeks in APOE(- 
389 /-) mice. Herein, we showed that treatment with a higher empagliflozin dose of 
390 10mg/Kg/day over a longer duration (10 weeks), may further reduce atheroma burden 
391 (approximately by 50%); an important factor contributing to this additional effect of 
392 empagliflozin could be the time of treatment initiation in relation to atheroma 
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393 formation. In the experiment by Han et al., mice were fed a HFD diet 13 weeks prior 
394 to the intervention with empagliflozin -vs 5 weeks in the present study-, and one 
395 could assume that the intervention at earlier stages of atheromatosis could contribute 
396 to more pronounced effects. Of note, we investigated the mRNA expression of SGLT-1 
397 and SGLT-2 in aorta vessel and we found that SGLT-1 was expressed in all samples 
398 while SGLT-2 was faintly detected in two of the samples (data not shown). Thus, it 
399 could be strongly hypothesized that direct effects of empagliflozin are mediated via 
400 SGLT-1 inhibition. 
 
401 MCP-1 is important mediator of the atherosclerosis process [Harrington et al. 2000]. A 
402 marked suppression of the local inflammatory cytokine expression may be the central 
403 mechanism involved. Of note, local gene silencing of MCP-1 expression, turned a 
404 vulnerable plaque into a more stable plaque phenotype in APOE(-/-) mice [Liu et al. 
405 2012]. In our study, expression of MCP-1 mRNA was reduced in Empa-group compared 
406 to controls, although immunohistochemistry revealed no significant changes. There 
407 are no studies investigating the effect of empagliflozin on MCP-1 expression locally in 
408 the atherosclerotic lesion, to date. Oezle et al. [2014] found lower MCP-1 expression 
409 in aortas excised from STZ-induced diabetic rats treated with 30mg/Kg/day, but not 
410 with 10mg/Kg/day empagliflozin for seven weeks compared to untreated; however, 
411 this model is not ideal for studying atherosclerosis. 
 
412 Another study showed that empagliflozin has no effect on MCP-1 transcription in renal 
413 cortex compared to control group, irrespective of glucose levels [Gangadharan Komala 
414 et al. 2014], while Han et al. using APOE(-/-) mice demonstrated decreased serum 
415 MCP-1 levels as well as decreased MCP-1 mRNA expression in adipocytes following 
416 empagliflozin administration for 8 weeks. Interestingly, in vitro experiments in human 
417 endothelial cells indicated that empagliflozin did not suppress IL-1β-stimulated MCP-1 
418 mRNA expression, whereas canagliflozin did so [Mancini et al. 2018]. In our previous 
419 work, canagliflozin given for 5 weeks reduced significantly the expression of MCP-1 
420 protein in atheroma lesion of APOE(-/-) mice [Nasiri-Ansari et al. 2018]. 
15  
421 In addition, we found that long-term administration of empagliflozin reduced the 
422 expression of VCAM-1 mRNA, albeit, this effect was not confirmed at protein level, 
423 similar to MCP-1 [Nasiri-Ansari et al. 2018]. 
424 In vitro experiments have shown that empagliflozin had no effect on TNFa induced 
425 secretion of ICAM-1 and VCAM-1 in HUVEC cells [Uthman et al. 2018], while Oezle et 
426 al. found decreased ICAM-1 mRNA expression in non-atherosclerotic aorta from STZ- 
427 induced diabetic rats treated with 30mg/Kg/day. 
428 Immunohistochemistry staining revealed that treatment with empagliflozin marginally 
429 reduced CD-68 and MMP-9 protein levels while marginally induced TIMP-1 expression 
430 in atherosclerotic lesions compared to control group. However, plaque collagen 
431 content did not differ significantly between the two groups. In line with was is 
432 reported by Han et al., empagliflozin did not affect significantly plaque stability as 
433 evaluated by collagen content and plaque smooth muscle cells (SMCs). However, 
434 there was a trend for reduced MMP-9 protein and increased TIMP-1/MMP-2 protein 
435 ratio in Empa-group compared to controls. It is possible that factors other than the 
436 ones measured herein influence more potently plaque stability. 
 
437 An important advantage of our study is that we evaluated factors (MMPs, TIMPs, MCP- 
438 1, ICAM-1, VCAM-1) known to play an important role in plaque vulnerability at both 
439 mRNA and active protein level in relation to the end point (i.e collagen content and 
440 SMCs), directly on atheroma plaque. Interestingly, we found equivocal results 
441 regarding MCP-1 and ICAM-1, highlighting the necessity of the evaluation of active 
442 protein apart from the transcripts. A possible explanation for this discrepancy could 
443 be an increased degradation rate of mRNA compared to protein [Panganiban et 
444 al.2014]. Scarce literature is available on the impact of SGLT2-i on plaque stability, 
445 and in most available studies, these factors have been evaluated at mRNA level only 
446 and/or in artery sections not corresponding to plaque lesion, giving thus misleading 
447 results [Nakatsu et al. 2017; Leng et al. 2016; Han et al. 2016]. 
 
448 448 
 
449 5.1 Conclusions 
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450 Although more mechanistic studies need to be performed, our study suggests that 
451 empagliflozin has anti-atherogenic properties affecting traditional CVD factors such as 
452 HDL-cholesterol, hypertension and heart rate, though not inducing weight loss. 
453 Undoubtedly, glucose lowering effects contribute to this result; however, there is 
454 sufficient evidence in the literature, suggesting that empagliflozin may have 
455 pleiotropic actions. In this study, we commenced empagliflozin administration after 5 
456 weeks of diet manipulation, when atherosclerosis process was established, and plaque 
457 formation was initiated. This therapeutic design was chosen to enhance the validity 
458 and fidelity of a model of secondary CVD prevention. We hypothesized that an earlier 
459 intervention  may  be  more  potent  in  attenuating  the  process  of  atheromatosis. 
460 Compositional changes in plaque like SMCs and collagen content were not found in the 
461 empagliflozin group confirming the absence of significant alterations in 
462 metalloproteinase system and inflammation. Moreover, studies with a longer 
463 duration, and/or earlier initiation of treatment in relation to initiation of 
464 atherosclerosis process (resembling a mouse-model for the study of primary 
465 prevention of CVD) will shed more light in the therapeutic potential of empagliflozin. 
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676 Figure 1. 
677 Total serum cholesterol, serum HDL, serum LDL and fasting blood glucose levels in Empa-group 
678 and Control-group before and after 10 weeks of Empagliflozin/vehicle oral administration. 
679 1a.Empa oral administration led to a significant reduction in total cholesterol and fasting blood 
680 glucose levels and a significant induction in HDL levels while had no effect on serum LDL levels. 
681 Fasting glucose levels were significantly increased in the control group at the end of 
682 intervention. 1b. Fasting blood glucose changes from baseline were significantly different 
683 between Empa- and Control-groups. Data are shown as mean±SD (**P< 0.01, *P<0.05) 
684 Figure 2. 
685 The effect of empagliflozin oral administration on diastolic, systolic blood pressure and heart 
686 rate of APOE(−/−) mice. 2a. 10 weeks of empagliflozin intervention significantly reduced heart 
687 rate while had no effect on systolic and diastolic blood pressure. A significant increase in 
688 diastolic blood pressure was observed in the control group after 10 weeks on intervention. 
689 2b. Diastolic blood pressure and heart rate changes from baseline were significantly different 
690 between two groups. Data are shown as mean±SD (**P<0.01, *P<0.05) 
691 Figure 3. 
692 Empagliflozin oral administration for 10 weeks marginally reduced atherosclerosis progress in 
693 APOE(−/−) mice. Arrows indicate atherosclerotic lesion sites. 3a.Representative images of H&E, 
694 Masson staining of aortic root. 3b. Quantification of free lumen area is shown as a percentage 
695 of free lumen by the total area of aortic root. The plaque collagen content was measured via 
696 quantification of Masson trichrome positive area over complete plaque area. Values are shown 
697 as mean±SD. Original magnification ×40. 
698 Figure 4. 
699  VCAM-1, MCP-1 and TIMP-1 mRNA levels (n=5) in aortic root of APOE(−/−) mice treated with 
700 empagliflozin/vehicle for 10 weeks. 4a.VCAM-1 and MCP-1 mRNA expression was significantly 
701 reduced in Empa-group, while TIMP-1 mRNA expression was marginally induced. 4b. TIMP- 
702 1/MMP-2 mRNA ratio was also significantly elevated in Empa-group (compared to Control- 
703 group). Data are shown as mean±SD (**P< 0.01, *P<0.05) 
704 Figure 5. 
705 Immunohistochemical analysis of atherosclerotic lesions on APOE(−/−) mice after empagliflozin 
706 oral administration. 5a. Representative images from the aortic root, immunostained for VCAM- 
707 1, TIMP-1, MMP-9 and CD68. 5b. Quantification of positive cell proportion stained for VCAM-1, 
708 TIMP-1, MMP-9 and CD68. Positive cell proportion stained with each antibody was scored as 
709 described previously. A marginal increase in TIMP-1 protein expression along with marginal 
710 reduction in MMP-9 and CD68 expression were observed in Empa-group as compared to the 
711 Control-group. Data are shown as mean±SD(P<0.1)(Original magnification ×40) 
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712 Supplementary figure 1. 
713 Changes in body weight in both groups in response to treatment/vehicle. 
714 
715 Supplementary figure 2. 
716 Immunohistochemical quantification of the positive cell proportion stained for α-ACTIN, MCP- 
717 1, MMP-2, TIMP-2 and ICAM-1. 
718 
Highlights (for review) 
 
 
 
 
Empagliflozin improves primary haemodynamic parameters and attenuates the 
development of atherosclerosis in high fat diet fed APOE knockout mice. 
 
 
Highlights: 
 Empagliflozin reduces heart rate and diastolic blood pressure in APOE(-/-) mice. 
 
 Empagliflozin reduces total cholesterol and increases HDL cholesterol. 
 
 Empagliflozin reduces atherosclerotic lesion formation. 
 
 Empagliflozin reduces VCAM-1 and MCP-1 inflammatory molecule expression. 
 Table 
 
 
 
 
Table 1. 
 
 
Target Gene Primer Sequence (Forward) Primer Sequence (Reverse) 
MMP-2 5/-CCCTCAAGAAGATGCAGAAGTTC-3/ 5/-TCTTGGCTTCCGCATGGT-3/ 
MMP-9 5/-CGTCGTGATCCCCACTTACT -3/ 5/-AACACACAGGGTTTGCCTTC -3/ 
TIMP-1 5/-GCATGGACATTTATTCTCCACTGT -3/ 5/-TCTCTAGGAGCCCCGATCTG -3/ 
TIMP-2 5/-TTCCGGGAATGACATCTATGG -3/ 5/-GGGCCGTGTAGATAAACTCGAT -3/ 
MCP-1 5/-GCATCCACGTGTTGGCTCA-3/ 5/-CTCCAGCCTACTCATTGGGATCA-3/ 
IL-6 5/-CCTCTGGTCTTCTGGAGTACC-3/ 5/-ACTCCTTCTGTGACTCCAGC-3/ 
ICAM-1 5/-GGTTCTCTGCTCCTCCACAT -3/ 5/-CCTTCCAGGCTTTCTCTTTG-3/ 
VCAM-1 5/-CTTCCAGAACCCTTCTCAG-3/ 5/-GGGACCATTCCAGTCACACTTC-3/ 
SGLT-1 5/- AAGATCCGGAAGAAGGCATC -3/ 5/- CAATCAGCACGAGGATGAAC -3/ 
SGLT-2 5/-GCAACATCGGCAGCGGTCAT-3/ 5/- GCGGAGGTACTGAGGCATTGTG-3/ 
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